Pathogenetic pathways leading to glioblastoma multiforme: Association between gene expressions and resistance to erlotinib

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3729-3732

  Löw, Sarah ^a   Vougioukas, Vassilios I ^b   Hielscher, Thomas ^c   Schmidt, Ursula ^c   Unterberg, Andreas ^a   Halatsch, Marc E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

cRNA microarrays; Erlotinib; Gene expression; Genetic pathways of pathogenesis; Glioblastoma multiforme

Indexed keywords

COMPLEMENTARY RNA; ERLOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CLASS 2BETA POLYPEPTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESPONSE; GENE EXPRESSION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; INSULIN LIKE GROWTH FACTOR 1 GENE; ONCOGENE; PHARMACOGENETICS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3 KINASE CLASS 2BETA POLYPEPTIDE GENE; PRIORITY JOURNAL; RNA HYBRIDIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 58149165340     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Halatsch M-E, Gehrke E, Vougioukas VI et al: Inverse correlation of epidermal growth factor receptor (EGFR) mRNA induction and suppression of anchorage-independent growth by OSI-774, an EGFR tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 100: 523-533, 2004.
2. Lang FF, Miller DC, Koslow M et al: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436, 1994.
3. Reyes-Mugica M, Rieger-Christ K, Ohgaki H et al: Loss of DCC expression and glioma progression. Cancer Res 57: 382-386, 1997.
4. Von Deimling A, Louis DN and Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995.
5. Diez D, Alvarez R and Dopazo A: Codelink: an R package for analysis of GE healthcare gene expression bioarrays. Bioinformatics 23: 1168-1169, 2007.
6. Van der Laan MJ, Dudoit S and Pollard KS: Part II. Step-down procedures for control of the family-wise error rate. Stat Appl Genet Mol Biol 3: Article 14, Epub June 14, 2004.
7. Trojan J, Cloix J-F, Ardourel M-Y et al: Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145: 795-811, 2007.
8. L. J Neurosurg 88: 884-889, 1998.
9. Knobbe CB and Reifenberger G: Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastoma. Brain Pathol 13: 507-518, 2003.
10. Halatsch M-E, Schmidt U, Behnke-Mursch J et al: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32: 74-89, 2006.
11. Halatsch M-E, Schmidt U, Bötefür IC et al: Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg 92: 297-305, 2000.
12. Weinstein IB and Joe AK: Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457, 2006.